Literature DB >> 1806609

Variations in the molecular forms of prolactin during the menstrual cycle, pregnancy and lactation.

M E Fonseca1, R Ochoa, C Morán, A Zárate.   

Abstract

Size heterogeneity of immunoreactive prolactin (PRL) was studied in serum samples obtained from eight normoprolactinemic women during the menstrual cycle and five additional patients at pregnancy and lactation. Gel filtration of sera from women with normal ovarian function tested at day 10-12th of their menstrual cycle showed two predominant PRL forms, approximately 22K and 26K mol wt. In addition two polymeric variants, 50K ("big" PRL) and 100K ("big-big" PRL) were found in less proportion, accounting for approximately 34% of the total PRL immunoreactivity detected in the sera. It was also noted a low mol wt form eluting around the region of 16K mol wt. In pregnant women the major PRL form was the 22K and its proportion showed a gradual increase as progression of gestation. The polymeric PRL forms were found in substantially less amount as gestation progressed. After parturition, in nursing mothers the 22K form remained prominent and in greater concentrations than the 26K monomeric variant. Large and low mol wt PRL forms were constantly detected in sera from women during the lactation period. From these data we confirmed that PRL circulates at various molecular forms and the relative proportion of these molecular variants exhibit changes according to the physiological state. In our study the predominant form was the 22K PRL (nonglycosylated) and it was of interest to discover the presence of a low mol wt PRL which elutes in the 16K area. The significance of this latter finding is not clear at the present.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1806609     DOI: 10.1007/BF03347114

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

1.  Heterogeneity of pituitary and plasma prolactin in man: decreased affinity of "Big" prolactin in a radioreceptor assay and evidence for its secretion.

Authors:  P E Garnier; M L Aubert; S L Kaplan; M M Grumbach
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

2.  Size heterogeneity of human prolactin in CSF and serum: experimental conditions that alter gel filtration patterns.

Authors:  K A Kiefer; W B Malarkey
Journal:  J Clin Endocrinol Metab       Date:  1978-01       Impact factor: 5.958

3.  Multiple molecular forms of prolactin during pregnancy in women.

Authors:  F Pansini; C M Bergamini; M Malfaccini; G Cocilovo; M Linciano; M Jacobs; B Bagni
Journal:  J Endocrinol       Date:  1985-07       Impact factor: 4.286

4.  A simple and effective solvent system for elution of gonadotropins from concanavalin A affinity chromatography.

Authors:  S Matsuura; H C Chen
Journal:  Anal Biochem       Date:  1980-08       Impact factor: 3.365

5.  Bioactivity of prolactin in a woman with an excess of large molecular size prolactin, persistent hyperprolactinemia and spontaneous conception.

Authors:  A N Andersen; H Pedersen; H Djursing; B N Andersen; H G Friesen
Journal:  Fertil Steril       Date:  1982-11       Impact factor: 7.329

6.  Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function.

Authors:  I S Fraser; Z G Lun; J P Zhou; A C Herington; G McCarron; I Caterson; K Tan; R Markham
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

7.  Further evidence that big,big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function.

Authors:  F Larrea; C Villanueva; M Carmen Cravioto; A Escorza; O del Real
Journal:  Fertil Steril       Date:  1985-07       Impact factor: 7.329

8.  Long-acting bromocriptine for the acute treatment of large macroprolactinomas.

Authors:  A Zarate; C Moran; R Miranda; M Loyo; M Medina; M E Fonseca
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

9.  Heterogeneity of human growth hormone and prolactin secreted in vitro: Immunoassay and radioreceptor assay correlations.

Authors:  J H Guyda
Journal:  J Clin Endocrinol Metab       Date:  1975-11       Impact factor: 5.958

10.  Multiple forms of pituitary prolactin, a glycosylated form of porcine prolactin with enhanced biological activity.

Authors: 
Journal:  Int J Pept Protein Res       Date:  1986-08
View more
  3 in total

1.  16 kDa prolactin reduces angiogenesis, but not growth of human breast cancer tumors in vivo.

Authors:  J M Faupel-Badger; E Ginsburg; J M Fleming; L Susser; T Doucet; B K Vonderhaar
Journal:  Horm Cancer       Date:  2010-04       Impact factor: 3.869

2.  Characterization of Δ7/11, a functional prolactin-binding protein.

Authors:  J M Fleming; E Ginsburg; C W McAndrew; C D Heger; L Cheston; J Rodriguez-Canales; B K Vonderhaar; P Goldsmith
Journal:  J Mol Endocrinol       Date:  2012-12-31       Impact factor: 5.098

3.  The effect of protein synthesis inhibitors on the glycosylation site occupancy of recombinant human prolactin.

Authors:  M Shelikoff; A J Sinskey; G Stephanopoulos
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.